| IKT |
Inhibikase Therapeutics, Inc. |
Common Stock, $0.001 par value |
9.9% |
$12,999,326 |
+$1,248,993 |
7,737,694 |
+11% |
ADAR1 Capital Management GP, LLC |
30 Jun 2025 |
| EQ |
Equillium, Inc. |
Common Stock, par value $0.0001 per share |
9.9% |
$8,858,062 |
|
6,194,882 |
|
ADAR1 Capital Management GP, LLC |
30 Sep 2025 |
| IBIO |
iBio, Inc. |
Common Stock, par value $0.001 per share |
9.9% |
$1,417,303 |
+$551,490 |
1,794,055 |
+64% |
ADAR1 Capital Management, LLC |
30 Jun 2025 |
| KPRX |
Kiora Pharmaceuticals, Inc. |
Common Stock, par value $0.01 per share |
9.9% |
$1,029,805 |
|
365,179 |
|
ADAR1 Capital Management GP, LLC |
30 Jun 2025 |
| ACST |
Grace Therapeutics, Inc. |
Common Stock, par value $0.0001 per share |
9.9% |
|
|
1,534,254 |
+2.1% |
ADAR1 Capital Management GP, LLC |
30 Sep 2025 |
| BIOA |
BioAge Labs, Inc. |
Common Stock, par value $0.00001 per share |
5.4% |
$9,298,190 |
|
1,937,123 |
|
ADAR1 Capital Management, LLC |
30 Jun 2025 |
| KALA |
KALA BIO, Inc. |
Common Stock, par value $0.001 per share |
4.9% |
$1,007,478 |
|
298,955 |
|
ADAR1 Capital Management, LLC |
31 Dec 2024 |
| ZURA |
ZURA BIO LIMITED |
Class A Ordinary Shares, par value $0.0001 per share |
3.2% |
$2,326,521 |
|
2,077,251 |
|
ADAR1 Capital Management, LLC |
31 Dec 2024 |
| PRTA |
Prothena Corporation Public Limited Company |
Ordinary Shares, par value $0.01 per share |
2.7% |
$14,338,396 |
-$18,601,691 |
1,469,098 |
-56% |
ADAR1 Capital Management, LLC |
30 Sep 2025 |
| CLRB |
Cellectar Biosciences, Inc. |
Common Stock, $0.00001 par value per share |
0.1% |
|
|
2,962 |
|
ADAR1 Capital Management, LLC |
30 Jun 2025 |
| KROS |
Keros Therapeutics, Inc. |
Common Stock, $0.0001 par value per share |
0% |
$0 |
-$85,258,156 |
0 |
-100% |
ADAR1 Capital Management, LLC |
15 Oct 2025 |